A Phase 3 interventional study of Tocilizumab (TCZ) and Placebo in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 62 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.
Among the 38 studies testing tocilizumab in COVID-19, this one is the 7th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 4th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Lebanese University · Sites in Lebanon
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 14 · Phase 4 2
First in 2016; this study’s year is marked. 34 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 150 across the 38 interventional studies. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing tocilizumab in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Drug: Tocilizumab (TCZ)
Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Drug: Placebo
Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
Time frame: Day 28
Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours
Defined as time from first dose of study drug to at least two NEWS2 assessments with a score of \<=2 covering a span of at least 21.5 hours, with a maximum of 26.5 hours between the first and last of these assessments and no assessments with a score \>2 in between. If one of the components of the NEWS2 score was missing at a particular time point, then the NEWS2 score was not calculated. Participants who died were censored at Day 28.
Time frame: Up to Day 28
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status
Time to improvement for this outcome measure was defined as the days from the first dose of study drug to when at least a 2-category improvement in clinical status (based on a 7-category ordinal scale) is observed. Participants who died were censored at Day 28.
Time frame: Up to Day 28
Time to Hospital Discharge or "Ready for Discharge"
Time to Hospital Discharge was defined as the time from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2L supplemental oxygen) Participants who died were censored at Day 28.
Time frame: Up to Day 28
Incidence of Mechanical Ventilation by Day 28
Participants who died by Day 28 were assumed to have required mechanical ventilation.
Time frame: Up to Day 28
Ventilator-Free Days to Day 28
Participants who died by Day 28 were assigned 0 ventilator-free days.
Time frame: Up to Day 28
Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4)
Participants who died by Day 28 were assumed to have required an ICU stay.
Time frame: Up to Day 28
Duration of ICU Stay to Day 28 (Week 4)
Participants who died by Day 28 were assigned a duration from the first dose of study drug to Day 28 at hour 23:59:59.
Time frame: Up to Day 28
Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
Time frame: Day 14
Time to Clinical Failure to Day 28 (Week 4)
Time to clinical failure was defined as the number of days from the first dose of study drug to the first occurrence on study of death, mechanical ventilation, ICU admission, or study withdrawal prior to discharge, whichever occurs first.
Time frame: Up to Day 28
Mortality Rate at Day 28 (Week 4)
Time frame: Day 28
Time to Recovery to Day 28 (Week 4)
Time to recovery was defined as the number of days from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) or non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen. Participants who died were censored at Day 28.
Time frame: Up to Day 28
Duration of Supplemental Oxygen to Day 28 (Week 4)
Participants who died by Day 28 were assigned a duration of 28 days of supplemental oxygen.
Time frame: Up to Day 28
| Milestone | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm |
|---|---|---|
| Started | 144 | 294 |
| Completed | 96 | 190 |
| Not completed | 48 | 104 |
| Withdrew: Withdrawal by subject | 4 | 10 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Lost to follow-up | 5 | 23 |
| Withdrew: Death | 35 | 71 |
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
| Percentage of Participants | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| 1 | 56.5 | 49.3 |
| 2 | 2.0 | 5.6 |
| 3 | 4.8 | 2.8 |
| 4 | 2.0 | 6.9 |
| 5 | 8.8 | 9.7 |
| 6 | 6.1 | 6.3 |
| 7 | 19.7 | 19.4 |
Defined as time from first dose of study drug to at least two NEWS2 assessments with a score of \<=2 covering a span of at least 21.5 hours, with a maximum of 26.5 hours between the first and last of these assessments and no assessments with a score \>2 in between. If one of the components of the NEWS2 score was missing at a particular time point, then the NEWS2 score was not calculated. Participants who died were censored at Day 28.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours | NA (NA to NA) | NA (NA to NA) |
Time to improvement for this outcome measure was defined as the days from the first dose of study drug to when at least a 2-category improvement in clinical status (based on a 7-category ordinal scale) is observed. Participants who died were censored at Day 28.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status | 14.0 (12.0 to 17.0) | 18.0 (15.0 to 28.0) |
Time to Hospital Discharge was defined as the time from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2L supplemental oxygen) Participants who died were censored at Day 28.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Time to Hospital Discharge or "Ready for Discharge" | 20.0 (17.0 to 27.0) | 28.0 (20.0 to NA) |
Participants who died by Day 28 were assumed to have required mechanical ventilation.
| Percentage of Participants | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm | TCZ - No Mechanical Ventilation at Baseline | Placebo - No Mechanical Ventilation at Baseline |
|---|---|---|---|---|
| Incidence of Mechanical Ventilation by Day 28 | 54.4 (48.7 to 60.1) | 60.4 (52.4 to 68.4) | 27.9 (21.4 to 34.4) | 36.7 (26.7 to 46.6) |
Participants who died by Day 28 were assigned 0 ventilator-free days.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Ventilator-Free Days to Day 28 | 22.0 (18.0 to 28.0) | 16.5 (11.0 to 26.0) |
Participants who died by Day 28 were assumed to have required an ICU stay.
| Percentage of Participants | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm | TCZ - Not in ICU at Baseline | Placebo - Not in ICU at Baseline |
|---|---|---|---|---|
| Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4) | 66.0 (60.6 to 71.4) | 71.5 (64.2 to 78.9) | 21.3 (14.1 to 28.4) | 35.9 (24.2 to 47.7) |
Participants who died by Day 28 were assigned a duration from the first dose of study drug to Day 28 at hour 23:59:59.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Duration of ICU Stay to Day 28 (Week 4) | 9.8 (7.0 to 15.7) | 15.5 (8.7 to 25.5) |
Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge") 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death
| Percentage of participants | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| 1 | 39.8 | 29.9 |
| 2 | 6.1 | 4.9 |
| 3 | 6.5 | 11.1 |
| 4 | 7.1 | 7.6 |
| 5 | 14.6 | 16.0 |
| 6 | 12.6 | 17.4 |
| 7 | 13.3 | 13.2 |
Time to clinical failure was defined as the number of days from the first dose of study drug to the first occurrence on study of death, mechanical ventilation, ICU admission, or study withdrawal prior to discharge, whichever occurs first.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Time to Clinical Failure to Day 28 (Week 4) | NA (NA to NA) | NA (21.0 to NA) |
| Percentage of Participants | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Mortality Rate at Day 28 (Week 4) | 19.7 (15.2 to 24.3) | 19.4 (13.0 to 25.9) |
Time to recovery was defined as the number of days from the first dose of study drug to hospital discharge or "ready for discharge" (normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) or non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen. Participants who died were censored at Day 28.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Time to Recovery to Day 28 (Week 4) | 16.0 (12.0 to 21.0) | 24.0 (18.0 to NA) |
Participants who died by Day 28 were assigned a duration of 28 days of supplemental oxygen.
| Days | Tocilizumab (TCZ) mITT Arm | Placebo Modified Intent-to-Treat (mITT) Arm |
|---|---|---|
| Duration of Supplemental Oxygen to Day 28 (Week 4) | 26.5 (19.0 to 28.0) | 28.0 (26.0 to 28.0) |
Collected over 60 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Arm (Safety-Evaluable Population) | 36/143 (25.2%) | 64/143 (44.8%) | 29/143 (20.3%) |
| Tocilizumab (TCZ) Arm (Safety-Evaluable Population) | 72/295 (24.4%) | 116/295 (39.3%) | 83/295 (28.1%) |
| Event | Placebo Arm (Safety-Evaluable Population) | Tocilizumab (TCZ) Arm (Safety-Evaluable Population) |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 20/143 | 36/295 |
| Septic shockInfections and infestations | 7/143 | 7/295 |
| COVID-19Infections and infestations | 2/143 | 14/295 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/143 | 5/295 |
| Cardiac arrestCardiac disorders | 5/143 | 4/295 |
| Acute kidney injuryRenal and urinary disorders | 4/143 | 10/295 |
| PneumoniaInfections and infestations | 4/143 | 7/295 |
| SepsisInfections and infestations | 4/143 | 3/295 |
| BacteraemiaInfections and infestations | 3/143 | 3/295 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 3/143 | 0/295 |
| Event | Placebo Arm (Safety-Evaluable Population) | Tocilizumab (TCZ) Arm (Safety-Evaluable Population) |
|---|---|---|
| Urinary tract infectionInfections and infestations | 5/143 | 22/295 |
| AnaemiaBlood and lymphatic system disorders | 10/143 | 17/295 |
| HypertensionVascular disorders | 3/143 | 20/295 |
| ConstipationGastrointestinal disorders | 8/143 | 18/295 |
| DiarrhoeaGastrointestinal disorders | 3/143 | 18/295 |
| PneumoniaInfections and infestations | 8/143 | 10/295 |
| Age, Continuous(Years) | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm | Total |
|---|---|---|---|
| Mean | 60.6 ± 13.7 | 60.9 ± 14.6 | 60.8 ± 14.3 |
| Sex: Female, Male(Participants) | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm | Total |
|---|---|---|---|
| Female | 43 | 89 | 132 |
| Male | 101 | 205 | 306 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 47 | 94 | 141 |
| Not Hispanic or Latino | 86 | 181 | 267 |
| Unknown or Not Reported | 11 | 19 | 30 |
| Race (NIH/OMB)(Participants) | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 8 | 13 |
| Asian | 10 | 28 | 38 |
| Native Hawaiian or Other Pacific Islander | 5 | 3 | 8 |
| Black or African American | 26 | 40 | 66 |
| White | 76 | 176 | 252 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 21 | 39 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org. Further details on Roche's criteria for eligible studies are available here: https://vivli.org. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm
Ran from Apr 2020 to primary completion in Jun 2020, 2 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab